PANTHERx® Specialty Pharmacy’s Chairman & CEO, Dr. Gordon J. Vanscoy presented Matthew Misorski, Pharm.D., with a certificate in recognition of his completion of the PANTHERx® Specialty Pharmacy Fellowship Program. Under the guidance of the program director Douglas Gebhard, Pharm.D., MBA, Dr. Misorski intensely trained in Business & Pharmacy Operations, Quality Improvement, Clinical & Education, Pharmacy […]

The National Association of Specialty Pharmacy (NASP) recently announced the launch of their new Student Association of Specialty Pharmacy (SASP) via a segment on the Pharmacy Podcast Network. The show, hosted by Sheila Arquette, NASP Executive Director, featured three members of NASP’s Education Committee including PANTHERx® Specialty Pharmacy’s, Doug Gebhard; Pharm.D., MBA. The now debuted […]

PANTHERx® Specialty Pharmacy announced today that it has entered into a partnership with The Health Plan as a provider of specialty pharmacy medications across multiple therapeutic categories. In addition, PANTHERx® will be the exclusive provider for the recently FDA-approved therapies CRYSVITA® (burosumab-twza) injection and JYNARQUE™ (tolvaptan). Through this partnership, The Health Plan and PANTHERx both […]

PANTHERx® Specialty Pharmacy announced today that it has expanded its preferred partnership with Highmark to include Crysvita™ (burosumab-twza). Crysvita™ (burosumab-twza) is the first FDA-approved therapy to treat adults and children ages one year and older with x-linked hypophosphatemia (XLH).  XLH causes low levels of phosphorus in the blood. It leads to impaired bone growth and […]

PANTHERx® Specialty Pharmacy’s Chairman & CEO, Dr. Gordon J. Vanscoy will be presenting a discussion on specialty pharmacy’s evolving role in rare disorders and orphan drugs at the upcoming 7th Orphan Drugs & Rare Diseases Americas West Coast Congress from June 25th – 26th in San Diego, California. The Orphan Drugs & Rare Diseases Global […]